*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Research on DNA vaccines is one of the most promising areas of life science study. Advances in the field are rapidly being made in industry as well as academia. Recent news includes:
Vical's announcement that results from a Phase I trial of a DNA vaccine for SARS demonstrated that the vaccine was well tolerated and induced neutralizing antibody responses in 80% of vaccinees and T-cell immune responses in all vaccinees.
Inovio Biomedical's report that its Swedish partner, Tripep, released positive interim results from a Phase I/II study of a therapeutic DNA vaccine against HCV. The vaccine, administered via Inovio's electroporation-based DNA delivery system, reduced viral load up to 99.7%
During this week's podcast, our roundtable panelists highlight the key DNA vaccine enabling technologies and pinpoint the main barriers to the successful development of human DNA vaccines. They discuss what the DNA vaccine business needs to do in 2009 and over the next five years to convince both the public and healthcare professionals that the field is on solid footing. Also explored are ideas on how to get big pharma back into the human DNA vaccine fold and strategies for encouraging industry and academia to work better together for DNA vaccine development.
Avtar Dhillon, M.D., President and CEO, Inovio Biomedical; Joseph Kim, Ph.D., Co-founder, President, and CEO, VGX Pharmaceuticals; Michael Egan, Ph.D., Director of Immunology, Profectus Biosciences; Jeffrey Ulmer, Ph.D., Global Head of External Research, Novartis Vaccines and Diagnostics; Alan King, Ph.D., Vice President, Cytopulse Sciences; Robert Bernard, President and CEO, Ichor Medical Systems.